{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:25:30Z","timestamp":1791275130069,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2012,8,29]],"date-time":"2012-08-29T00:00:00Z","timestamp":1346198400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1007\/s00277-012-1534-y","type":"journal-article","created":{"date-parts":[[2012,8,28]],"date-time":"2012-08-28T09:42:14Z","timestamp":1346146934000},"page":"1765-1772","source":"Crossref","is-referenced-by-count":13,"title":["Current treatment of mantle cell lymphoma: results of a national survey and consensus meeting"],"prefix":"10.1007","volume":"91","author":[{"given":"M.","family":"Witzens-Harig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Hess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Atta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Zaiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Scholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Repp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Reiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Pott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Pelz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"La Ros\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Kirchner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Kiewe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Buske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Viardot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Dreyling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,8,29]]},"reference":[{"key":"1534_CR1","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","year":"2008","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds) (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon, France"},{"issue":"4","key":"1534_CR2","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","volume":"27","author":"A Herrmann","year":"2009","unstructured":"Herrmann A, Hoster E, Zwingers T, Brittinger G, Engelhard M, Meusers P, Reiser M, Forstpointner R, Metzner B, Peter N, W\u00f6rmann B, Tr\u00fcmper L, Pfreundschuh M, Einsele H, Hiddemann W, Unterhalt M, Dreyling M (2009) Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 27(4):511\u2013518","journal-title":"J Clin Oncol."},{"key":"1534_CR3","doi-asserted-by":"crossref","unstructured":"Dreyling M, Hiddemann W (2009) Current treatment standards and emerging strategies in mantle cell lymphoma. Am Soc Hematol Educ Program Book Hematol 542\u2013554","DOI":"10.1182\/asheducation-2009.1.542"},{"key":"1534_CR4","doi-asserted-by":"crossref","unstructured":"Hoster E, Metzner B, Forstpointner R, Pfreundschuh M, Tr\u00fcmper L, Hallek M, W\u00f6rmann B, D\u00fchrsen U, Gisselbrecht C, Kluin-Nelemans H, van Hoof A, Unterhalt M, Hiddemann W, Dreyling M (2009) Autologous stem cell transplantation and addition of rituximab independently prolong response duration in advanced stage mantle cell lymphoma. Blood 114(suppl 1):#880","DOI":"10.1182\/blood.V114.22.880.880"},{"key":"1534_CR5","doi-asserted-by":"crossref","unstructured":"Kluin-Nelemans JC, Hoster E, Hermine O, Walewski J, Trneny M, Geisler C, Stilgenbauer S, Thieblemont C, Vehling-Kaiser U, Doorduikn J, Coiffier B, Forstpointner R, Tilly H, Kanz L, Feugier P, Szymczyk M, Hallek M, Kremers S, Lepeu S, Sanhes L, Zijlstra J, Bouabdallah R, Lugtenburg P, Macro M, Pfreundschuh M, Prochazka V, Di Raimondo F, Ribrag V, Uppenkamp M, Andre A, Klapper W, Hiddemann W, Unterhalt M, Dreyling M (2012) Therapy in older patients with mantle cell lymphoma. New Engl J Med 2012 (in press).","DOI":"10.1056\/NEJMoa1200920"},{"issue":"7","key":"1534_CR6","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"M Dreyling","year":"2005","unstructured":"Dreyling M, Lenz G, Hoster E, van Hoof A, Gisselbrecht C, Schmits R, Metzner B, Truemper L, Reiser M, Steinhauer H, Boiron J, Boogaerts M, Aldaoud A, Silingardi V, Kluin-Nelemans H, Hasford J, Parwaresch R, Unterhalt M, Hiddemann W (2005) Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 105(7):2677\u20132684","journal-title":"Blood"},{"issue":"9","key":"1534_CR7","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","volume":"23","author":"G Lenz","year":"2005","unstructured":"Lenz G, Dreyling M, Hoster E, W\u00f6rmann B, D\u00fchrsen U, Metzner B, Eimermacher H, Neubauer A, Wandt H, Steinhauer H, Martin S, Heidemann E, Aldaoud A, Parwaresch R, Hasford J, Unterhalt M, Hiddemann W (2005) Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 23(9):1984\u20131992","journal-title":"J Clin Oncol"},{"key":"1534_CR8","doi-asserted-by":"crossref","unstructured":"Hoster E, Unterhalt M, W\u00f6rmann B, D\u00fchrsen U, Metzner B, Eimermacher H, Neubauer A, Wandt H. Steinhauer H, Martin S, Heidemann E, Aldaoud A, Hiddemann W, Dreyling M (2008) The addition of rituximab to first-line chemotherapy (R-CHOP) results in superior response rates, time to treatment failure and response duration in patients with advanced stage mantle cell lymphoma: long term results of a randomized GLSG trial. Blood 112(suppl 1):#3049","DOI":"10.1182\/blood.V112.11.3049.3049"},{"key":"1534_CR9","doi-asserted-by":"crossref","unstructured":"Hermine O, Hoster E, Walewski J, Ribrag V, Brousse N, Thieblemont C, Bouabdallah R, Stilgenbauer S, Feugier P, Forstpointner R, Haioun C, Kneba M, H\u00e4nel M, - Casasnovas R, Finke J, Hallek M, Wandt H, Bosly A, Klapper W, Gisselbrecht C, Coiffier B, Hiddemann W, Unterhalt M, Dreyling M (2010) \u201cAlternating courses of 3\u00d7 CHOP and 3\u00d7 DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) is superior to 6 courses CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: results of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net).\u201d Blood 116(Suppl. 1):#110","DOI":"10.1182\/blood.V116.21.110.110"},{"issue":"7","key":"1534_CR10","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","volume":"112","author":"CH Geisler","year":"2008","unstructured":"Geisler CH, Kolstad A, Laurell A, Jerkeman M, R\u00e4ty R, Andersen NS, Pedersen LB, Eriksson M, Nordstr\u00f6m M, Kimby E, Bentzen H, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Ehinger M, Sundstr\u00f6m C, Delabie J, Karjalainen-Lindsberg ML, Brown P, Elonen E (2008) Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 112(7):2687\u20132693","journal-title":"Blood"},{"key":"1534_CR11","first-page":"453a","volume":"88","author":"M Unterhalt","year":"1996","unstructured":"Unterhalt M, Hermann R, Koch P, Tr\u00fcmper L, Bodenstein H, Dietzfelbinger H, Landys K, Reu\u00df M, Vetter H, Maschmeyer G, Freund M, Neubauer A, Engert A, Stauder R, Herold M, Tiemann M, Parwaresch R, Stein H, Hiddemann W (1996) Long term interferon alpha maintenance prolongs remission duration in advanced low grade lymphomas and is related to the efficacy of initial cytoreductive chemotherapy. Blood 88(suppl 1):453a","journal-title":"Blood"},{"key":"1534_CR12","doi-asserted-by":"crossref","unstructured":"Rummel M (2009) \u201cBendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany)\u201d Blood 114(No 21): #405.","DOI":"10.1182\/blood.V114.22.405.405"},{"issue":"23","key":"1534_CR13","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","volume":"27","author":"G Hess","year":"2009","unstructured":"Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C, Laurell A, Offner F, Strahs A, Berkenblit A, Hanushevsky O, Clancy J, Hewes B, Moore L, Coiffier B (2009) Phase III study to evaluate temsirolimus compared with investigator\u2019s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 27(23):3822\u20133829","journal-title":"J Clin Oncol"},{"key":"1534_CR14","unstructured":"Zoellner A, Bayerl S, Weinkauf M, Hiddemann W, Dreyling M (2011) Temsirolimus and chemotherapy show additive effects and target independent cell programs (cell cycle, apoptosis) in diffuse large cell B cell lymphoma. Onkologie Band 34(suppl 6):#P271"},{"key":"1534_CR15","doi-asserted-by":"crossref","unstructured":"Hess G, Keller U, Atta J, Buske C, Borchmann P, Medler C, Witzens-Harig M, Dreyling M (2011) Temsirolimus in combination with bendamustine and rituximab for the treatment of relapsed mantle cell and follicular lymphoma: report on an ongoing phase I\/II trial. Blood 118(suppl 1):#2697","DOI":"10.1182\/blood.V118.21.2697.2697"},{"issue":"4","key":"1534_CR16","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1470-2045(11)70062-6","volume":"12","author":"S Ansell","year":"2011","unstructured":"Ansell S, Tang H, Kurtin PJ, Koenig PA, Inwards DJ, Shah K, Ziesmer SC, Feldman AL, Rao R, Gupta M, Erlichman C, Witzig TE (2011) Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. Lancet Oncol 12(4):361\u2013368","journal-title":"Lancet Oncol"},{"issue":"1","key":"1534_CR17","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0092-8674(94)90396-4","volume":"79","author":"A Ciechanover","year":"1994","unstructured":"Ciechanover A (1994) The ubiquitin-proteasome proteolytic pathway. Cell 79(1):13\u201321","journal-title":"Cell"},{"issue":"6","key":"1534_CR18","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1158\/1078-0432.CCR-07-2218","volume":"14","author":"RZ Orlowski","year":"2008","unstructured":"Orlowski RZ, Kuhn DJ (2008) Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 14(6):1649\u20131657","journal-title":"Clin Cancer Res"},{"issue":"30","key":"1534_CR19","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","volume":"24","author":"RI Fisher","year":"2006","unstructured":"Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, Epner E, Krishnan A, Leonard JP, Lonial S, Stadtmauer EA, O\u2019Connor OA, Shi H, Boral AL, Goy A (2006) Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 24(30):4867\u20134874","journal-title":"J Clin Oncol"},{"issue":"1","key":"1534_CR20","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1365-2141.2008.07466.x","volume":"145","author":"O O\u2019Connor","year":"2009","unstructured":"O\u2019Connor O, Moskowitz C, Portlock C, Hamlin P, Straus D, Dumitrescu O, Sarasohn D, Gonen M, Butos J, Neylon E, Hamelers R, Mac-Gregor Cortelli B, Blumel S, Zelenetz AD, Gordon L, Wright JJ, Vose J, Cooper B, Winter J (2009) Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre phase 2 clinical trial. Br J Haematol 145(1):34\u201339","journal-title":"Br J Haematol"},{"issue":"6","key":"1534_CR21","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/j.1365-2141.2009.07775.x","volume":"146","author":"J Gerecitano","year":"2009","unstructured":"Gerecitano J, Portlock C, Moskowitz C, Hamlin P, Straus D, Zelenetz AD, Zhang Z, Dumitrescu O, Sarasohn D, Lin D, Pappanicholaou J, Cortelli BM, Neylon E, Hamelers R, Wright J, O\u2019Connor OA (2009) Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma. Br J Haematol 146(6):652\u2013655","journal-title":"Br J Haematol"},{"issue":"7","key":"1534_CR22","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.3324\/haematol.2011.041392","volume":"96","author":"W Lamm","year":"2011","unstructured":"Lamm W, Kaufmann H, Raderer M, Hoffmann M, Chott A, Zielinski C, Drach J (2011) Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma. Haematologica 96(7):1008\u20131014","journal-title":"Haematologica"},{"issue":"10","key":"1534_CR23","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1182\/blood-2010-11-314708","volume":"117","author":"J Friedberg","year":"2011","unstructured":"Friedberg J, Vose J, Kelly JL, Young F, Bernstein SH, Peterson D, Rich L, Blumel S, Proia NK, Liesveld J, Fisher RI, Armitage JO, Grant S, Leonard JP (2011) The combination of bendamustine, bortezomib, and rituximab for patients with relapsed\/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood 117(10):2807\u20132812","journal-title":"Blood"},{"issue":"5","key":"1534_CR24","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1080\/10428190902856790","volume":"50","author":"O Weigert","year":"2009","unstructured":"Weigert O, Weidmann E, Mueck R, Bentz M, von Schilling C, Rohrberg R, Jentsch-Ullrich K, Hiddemann W, Dreyling M (2009) A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma\u2014long-term results of a multicenter observation study. Leuk Lymphoma 50(5):716\u2013722","journal-title":"Leuk Lymphoma"},{"issue":"30","key":"1534_CR25","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1200\/JCO.2007.15.3429","volume":"26","author":"P Wiernik","year":"2008","unstructured":"Wiernik P, Lossos I, Tuscano JM, Justice G, Vose JM, Cole CE, Lam W, McBride K, Wride K, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis JB, Habermann TM (2008) Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin\u2019s lymphoma. J Clin Oncol 26(30):4952\u20134957","journal-title":"J Clin Oncol"},{"issue":"3","key":"1534_CR26","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2141.2009.07626.x","volume":"145","author":"T Habermann","year":"2009","unstructured":"Habermann T, Lossos I, Justice G, Vose JM, Wiernik PH, McBride K, Wride K, Ervin-Haynes A, Takeshita K, Pietronigro D, Zeldis JB, Tuscano JM (2009) Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol 145(3):344\u2013349","journal-title":"Br J Haematol"},{"issue":"7","key":"1534_CR27","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/annonc\/mdq626","volume":"22","author":"TE Witzig","year":"2011","unstructured":"Witzig TE, Vose JM, Zinzani PL, Reeder CB, Buckstein R, Polikoff JA, Bouabdallah R, Haioun C, Tilly H, Guo P, Pietronigro D, Ervin-Haynes AL, Czuczman MS (2011) An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin\u2019s lymphoma. Ann Oncol 22(7):1622\u20131627","journal-title":"Ann Oncol."},{"issue":"3","key":"1534_CR28","doi-asserted-by":"crossref","first-page":"416","DOI":"10.3324\/haematol.2011.051813","volume":"97","author":"F Zaja","year":"2012","unstructured":"Zaja F, De Luca S, Vitolo U, Orsucci L, Levis A, Salvi F, Rusconi C, Ravelli E, Tucci A, Bottelli C, Balzarotti M, Brusamolino E, Bonfichi M, Pileri SA, Sabattini E, Volpetti S, Monagheddu C, Vacca A, Ria R, Fanin R (2012) Salvage treatment with lenalidomide and dexamethasone in relapsed\/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers. Haematologica 97(3):416\u2013422","journal-title":"Haematologica"},{"issue":"27","key":"1534_CR29","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1056\/NEJM199912303412706","volume":"341","author":"LF Hutchins","year":"1999","unstructured":"Hutchins LF, Unger JM et al (1999) Underrepresentation of patients 65\u00a0years of age or older in cancer-treatment trials. N Engl J Med 341(27):2061\u20132067","journal-title":"N Engl J Med"},{"issue":"(suppl 1)","key":"1534_CR30","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1182\/blood.V118.21.442.442","volume":"118","author":"L Wang","year":"2011","unstructured":"Wang L, Martin P, Blum KA, Kahl BS, Maeda LS, Advani R, Williams ME, Rule S, Rodriguez S, Pang CF, Hedrick E, Goy A (2011) The Bruton\u2019s tyrosine kinase inhibitor PCI-32765 is highly active as single-agent therapy in previously-treated mantle cell lymphoma (MCL): preliminary results of a phase II trial. Blood 118(suppl 1):#442","journal-title":"Blood"},{"issue":"suppl 4","key":"1534_CR31","first-page":"iv85","volume":"19","author":"M Herold","year":"2008","unstructured":"Herold M, Haas A, Doerken B, Neser S, Al Ali K, Neubauer A, D\u00f6lken G (2008) R-MCP) in advanced mantle cell lymphoma is not superior to chemotherapy (MCP) alone - 50\u00a0months up date of the OSHO phase III study. Ann Oncol 19(suppl 4):iv85, #012","journal-title":"Ann Oncol"},{"issue":"2","key":"1534_CR32","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2141.2010.08228.x","volume":"150","author":"J Romaguera","year":"2010","unstructured":"Romaguera J, Fayad L, McLaughlin P, Pro B, Rodriguez A, Wang M, Weaver P, Hartig K, Kwak LW, Feldman T, Smith J, Ford P, Goldberg S, Pecora A, Goy A (2010) Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with rituximab-high dose methotrexate\/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 150(2):200\u2013208","journal-title":"Br J Haematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-012-1534-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-012-1534-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-012-1534-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,28]],"date-time":"2024-04-28T19:22:58Z","timestamp":1714332178000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-012-1534-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,29]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["1534"],"URL":"https:\/\/doi.org\/10.1007\/s00277-012-1534-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,29]]}}}